Studies have shown that erythrocyte membranes are present within necrotic cores in atherosclerotic plaques, and that circulating erythrocytes in patients with acute coronary syndrome (ACS) have increased total cholesterol content (CEM). binds to erythrocytes and during intraplaque haemorrhage it is released into the plaque and thus may contribute to inflammatory cascade and atherosclerotic plaque instability. The present study was undertaken to test the hypothesis that erythrocyte membrane IL-8 is elevated in patients with ACS compared with those with chronic stable angina (CSA).
Introduction
It has been suggested that erythrocytes could play an active role in the development of atherosclerotic plaque and in plaque instability. 1, 2 Studies have shown that the necrotic lipid core of atherosclerotic plaques contains erythrocyte membranes 3, 4 and that total cholesterol levels in the membrane of circulating erythrocytes (CEM) was increased in patients with acute coronary syndrome (ACS) compared with patients with chronic stable angina (CSA). 5 It has been proposed that red blood cells (RBC) rich in cholesterol may contribute to atherosclerotic plaque expansion leading to its instability. 1, 6 It is also possible that RBC membranes released within the lipid core during intraplaque haemorrhage, which contain inflammatory mediators, such as interleukin-8 (IL-8) may contribute to plaque growth and instability. 2,4,7 -12 The present study was undertaken to investigate whether patients with ACS have higher erythrocyte IL-8 (rIL-8) concentrations compared with patients with CSA.
Methods

Patients population
From November 2006 to September 2007, 312 consecutive patients who were admitted to our institution for the assessment of their coronary artery status were recruited prospectively. From those, 20 who did not meet the inclusion criteria (described later), five who refused to give their informed consent and 13 in whom data collection was not complete were excluded from further analysis. The remaining 274 patients represented the study population. Of those, 120 had CSA, and 118 ACS, 58 (49%) with ST-segment elevation myocardial infarction (STEMI), 32 (27%) with non-STEMI (NSTEMI) and 28 (24%) with unstable angina (UA). In addition, 36 patients with chest pain and angiographically normal coronary arteries (NCA) were also included in the study.
CSA was defined as typical exertional chest pain, relieved by rest and/or nitrates, without a change in frequency or severity for 3 months prior to study entry, and one of the following: a positive response (.1 mm ST-segment depression) on the exercise stress test; reversible or fixed myocardial perfusion defect(s) during myocardial perfusion scintigraphy; segmental wall motion abnormalities at rest or during stress echocardiography. 13 Myocardial infarction (MI) was diagnosed in the presence of prolonged (.20 min) chest pain, with ST-segment changes suggestive of myocardial ischaemia or necrosis on the standard 12-lead electrocardiogram (ECG) associated with increased serum markers of myocardial necrosis measured on at least two occasions during the first 24 h after the index event (increase above the 99th percentile of the upper reference limit of creatine kinase-myocardial fraction and troponin-T). 14 Only patients with spontaneous MI (type 1) were recruited. Patients presented with MI secondary to ischaemia due to increased oxygen demand or decreased supply (type 2), after cardiac arrest with successful resuscitation and findings consistent with myocardial ischaemia (type 3), MI associated with percutaneous coronary intervention within the first 48 h after the procedure (type 4a) or stent thrombosis, as documented by coronary angiography (type 4b), or MI associated with coronary artery bypass grafting within the first 72 h after the procedure (type 5) 14 were not included in the study.
MI patients were considered to have STEMI when an elevation of the ST-segment !0.2 mV was detected in V 1 through V 3 and/or an elevation !0.1 mV was found in two or more contiguous ECG leads. 15 NSTEMI was diagnosed in the presence of new horizontal or down-sloping ST-segment depression (!0.05 mV) and/or T-wave inversion (!0.1 mV) in two or more contiguous leads. 16 UA was defined as anginal pain at rest fulfilling Braunwald's IIIb criteria with transient significant ischaemic ST-segment or T-wave changes, or both, without biochemical evidence for myocardial damage. 17 Patients with unstable coronary artery disease (CAD) (STEMI, NSTEMI, UA) who underwent urgent cardiac catheterization were not included in the study, since the acute event may have influenced laboratory measurements.
NCA patients group comprised individuals with CAD risk factors who presented with chest pain and were found to have NCA on coronary angiography.
Patients with a history of excessive alcohol intake, haematological, renal, liver, or thyroid diseases, or malignancies were excluded. Furthermore, patients with infectious or autoimmune diseases, familial hyperlipidaemia, and those who underwent surgical procedures in the preceding 3 months were excluded from the study. None of the patients were receiving anti-inflammatory drugs or hormone replacement therapy. Patients with abnormal RBC counts (,4.7 and .5.9 Â 10 6 per mL for men and ,4.2 and .5.4 Â 10 6 per mL for women) and/or abnormal haemoglobin levels (,13 and .18 g/dL for men and ,12 and .16 g/dL for women) were also excluded. The study was approved by the Local Research Ethics Committee, and all patients gave written informed consent prior to study entry.
Angiographic analysis
Coronary arteriography was performed using the Judkins technique; images of the coronary artery tree were obtained on routine, standardized projections with the digital GE ADVANTX LCþ System (General Electric Medical Systems, S.C.S., Buc, France). Coronary arteriography was performed within 8 -23 days (median 14) from the acute ischaemic episode in patients with ACS and at least 3 months after an acute episode in patients with CSA. Patients with chest pain and NCA were studied within 2 weeks from the time of their referral for coronary arteriography. Two experienced cardiologists who had no knowledge of the patients' clinical characteristics and biochemical results visually reviewed all angiographic images to assess the extent and severity of CAD using an automated quantitative coronary artery stenosis assessment process (GE Centricity Cardiology CA 1000 Cardiac Review 1.0, General Electric Medical Systems). Vessel score was used to assess the extent of the atherosclerotic disease in the coronary artery tree. Vessel score is based on the number of diseased coronary arteries, where a coronary artery is regarded as 'diseased' in the presence of !75% reduction in lumen diameter. 18, 19 Interobserver variability for vessel and stenosis score was 3.1 and 4.2%, respectively.
Laboratory analysis
Peripheral blood samples were obtained from all patients after a 12 h overnight fast, at the time of coronary angiography prior to heparin infusion and to injection of any angiographic contrast material. Blood specimens for rIL-8 and CEM analysis were collected in standard vacutainer tubes containing citrate. A 3 mL aliquot of venous blood collected in citrate plasma tubes was centrifuged at 1500 r.p.m. for 10 min at 48C; the plasma and buffy coat were carefully removed by aspiration. Aliquots of plasma were stored at 2208C for IL-8 estimation (pIL-8), and the remaining RBC were resuspended and washed twice in 154 mM NaCl isotonic solution. 20 
Isolation of erythrocyte membranes
Erythrocyte membranes were obtained according to the method previously reported 5 ensuring minimal haemoglobin contamination. The procedure was carried out as follows: 1 mL of washed erythrocytes solution was hypotonically lysed in 30 volumes of cold haemolysis buffer (1 mM Tris -HCl, 1 mM EDTA, 10 mM NaCl, pH 7.2), mixed by vortex and allowed to stand for 15 min. Membranes were separated from the haemolysate (supernatant from haemolysed RBC) by centrifugation at 15 000 r.p.m. for 15 min at 48C; this step was repeated three times until a white/pale pink pellet containing haemoglobin-free erythrocytes (ghosts) was obtained. 21 Erythrocyte ghosts were resuspended in 1 mL of PBS (phosphate buffered saline) and stored at 2208C until further analysis. A 125 mL aliquot of membrane suspension was used to determine D.N. Tziakas et al.
membrane protein concentration by the method of Bradford using bovine serum albumin as a standard. 22 Red blood cell membrane lipid extraction and cholesterol estimation Erythrocyte membrane samples (10 mg of protein), were extracted by vigorous vortexing with 200 mL of chloroform-Triton X-100 (1% Triton X-100 in pure chloroform). The extracts were centrifuged for 5 min in a microcentrifuge, at top speed. The organic phase (lower phase) was collected and air dried at 508C to remove chloroform. The remaining dried lipids (in Triton X-100) were then processed for cholesterol determination. This extraction procedure was recommended as appropriate for the subsequent total cholesterol content of RBC membrane lipid extracts measurements; using a colorimetric assay kit by BioVision (Cholesterol/Cholesteryl Ester Quantification Kit -BioVision Research Products, Mountain View, CA, USA) with a lower detection limit of 2 mg. 23 The assay kit is suitable for measuring total cholesterol by prior incubation of all samples in the presence of cholesterol esterase included in the reaction medium. Intra-and inter-assay precision were both ,2%. A 6 point calibration curve was prepared by diluting the Standard Solution provided in the kit, the absorbance of each sample was measured against blank at 570 nm and the result was plotted against the calibration curve to obtain the amount of total cholesterol. All the samples were measured in duplicates and none of the duplicates had a coefficient variation (CV) .3%. We were able to measure the amount of cholesterol in all the samples assayed. Results are expressed as micrograms of membrane cholesterol (total) per milligram of membrane protein.
Plasma and red blood cell-bound interleukin-8 estimation IL-8 was measured in plasma obtained as described earlier. For erythrocyte-bound IL-8, 1 mL of packed erythrocytes was washed four times with 0.9% NaCl (200 g for 10 min) to eliminate the remains of plasma, leucocytes, and platelets. The RBCs were adjusted to the original whole blood volume, and were lysed by adding Triton X-100 at a final concentration of 0.1%. 24 The lysates were stored at 2208C. The removal of leucocytes as well as steady IL-8 RBC-bound concentrations during the purification procedure were shown by measuring concentrations of myeloperoxidase (MPO)-a leucocyte specific peroxidase-and IL-8 at each different step. In detail, at each step after centrifugation, the buffy coat was removed and discarded together with the top layer of sedimented RBCs at a height of 5 mm. Following, a sample of 100 mL (samples S#1, S#2, S#3, S#4) was taken from the packed RBCs, solubilized with Triton X-100 at a final concentration of 0.1% and kept for analysis. At each step during the purification procedure declining MPO levels were observed reaching non-detectable by the assay concentrations at the final separation steps (S#1 390 + 29 ng/mL, S#2 46 + 18 ng/mL, S#3 and S#4 non-detectable concentrations). Furthermore, steady IL-8 RBC-bound levels were shown at each separation step (S#1 79 + 15 pg/mL, S#2 40 + 6 pg/mL, S#3 36 + 7 pg/mL and S#4 35 + 4 pg/mL).
MPO concentrations were measured using an ELISA kit (Quantikine, Human MPO, R&D Systems Inc., Minneapolis, MN, USA). IL-8 concentrations in plasma and erythrocyte lysates were measured with an ELISA kit (AviBion Human IL-8 ELISA -Orgenium Laboratories, Helsinki, Finland) with a lower detection limit of ,7 pg/mL. Plasma samples were treated as recommended by the manufacturers, whereas in the case of RBC lysates, 0.1% Triton X-100 was included in the supplied sample dilution buffer used in the initial incubation step, both with respect to blank, standards or samples alike.
Intra-and inter-assay precision was ,5.2 and ,6.4%, respectively. Briefly, an eight-point calibration curve was prepared by diluting the Standard Solution provided in the kit, the absorbance of each sample was measured against the blank at 450 nm. The result was plotted against the calibration curve to obtain the amount of IL-8. All the samples were measured in duplicates and none of the duplicates had a CV .4%. Results are expressed as picograms of IL-8 per millilitre of plasma.
Statistical analysis
Continuous variables are presented as means + 1 standard deviation (SD) except in Figure 1 where they are presented as medians with interquartile ranges and as percentages for categorical data. Comparisons between categorical variables were performed with the x 2 test or
Fisher's exact test as appropriate. Unadjusted comparisons were made by the Student's unpaired t-test, in order to evaluate differences in continuous variables between the two groups. Bonferroni's correction was used when appropriate. The planned sample size allowed a power of 90% for the independent comparison (rIL-8 levels between ACS vs. CSA) with a type 1 error probability of 0.05, assuming a mean difference equal to one half SD, on log-transformed data. Normality was tested using the Kolmogorov-Smirnov test. CEM, CRP (C-reactive protein), triglycerides, pIL-8 and rIL-8 levels were not normally distributed and were therefore logarithmically transformed as required to approach normal distribution and to obtain equal variances. Analysis of variance with covariates (ANCOVA) was used to evaluate differences in CEM, pIL-8 and rIL-8 levels between CSA and ACS after adjustment for all the variables that were significantly different between the two groups. Similarly, ANCOVA method was used to assess differences in the under investigation variables between ACS vs. NCA and CSA vs. NCA group. 
IL-8 content of erythrocyte membrane and ACS
Simple logistic regression analysis was used to assess univariate associations among the three biochemistry indices (rIL-8, CEM, and CRP) and CAD status (stable CAD vs. ACS). Odds ratios (OR) with 95% confidence intervals (CI) were calculated. OR for standardized log-transformed continuous variables reflect the relative risk for an increase of 1 SD (of the transformed variable) in the measure. 25 Multiple logistic regression analysis was also used to assess the independent adjusted relationship between these indices and CAD status with independent variables being those that were significantly different between the two groups (ACS vs. CSA). The basic assumption of linearity was assessed by plotting residuals vs. model predicted values, for all dependent variables in each model.
The independent predictive ability of rIL-8 levels for CAD clinical presentation was assessed using logistic regression models controlled for CRP and CEM in a stepwise fashion (covariates þ rIL-8, covariates þ rIL-8 þ CRP levels, covariates þrIL-8 þ CRP þ CEM levels). The additive predictive ability of rIL-8 levels for CAD status was tested using logistic regression models which additionally controlled for CRP and CEM levels in an inverse stepwise fashion (covariates þ CRP levels, covariates þ CRP þ CEM levels, covariates þ CRP þ CEM þ rIL-8 levels); we compared the predictive ability of these logistic regression models using the likelihood ratio-test and the C-statistic.
In addition, the prognostic ability of rIL-8 in the subgroup of patients with low and high CRP levels using its median value (5 mg/L) as cut-off point (this level is considered to represent a clinically relevant concentration associated with increased cardiovascular risk 26 ), was tested. Correlation analysis between variables was carried out by means of Spearman's correlation coefficient (r). Receiver-operating characteristic (ROC) curves were calculated for rIL-8, CEM, and CRP levels. A P-value ,0.05 was considered to indicate statistical significance with exception of pair-wise comparisons where Bonferroni's correction was applied [P ¼ 0.05/n (n ¼ number of pair-wise comparisons)]; all tests were two-sided. The SPSS 11.0 statistical software package (SPSS Inc., Chicago, IL, USA) was used for all calculations.
Results
Baseline characteristics
Baseline characteristics in patients with CSA, ACS, and those with NCA are presented in Table 1 . At the time of study entry, therapy with b-blockers, statins, nitrates, calcium channel blockers, and aspirin, was more common in CSA compared with other two groups. Severity of CAD as determined by angiography was similar between CSA and ACS patients.
No differences were observed in leucocyte (P ¼ 0.837), neutrophil (P ¼ 0.883), lymphocyte (P ¼ 0.662) count or neutrophils/ lymphocytes ratio (P ¼ 0.161) among the three groups.
Erythrocyte membrane and plasma measurements
Content of rIL-8 was significantly higher (P , 0.001) in ACS (102.9 + 70. 1 pg/mL) compared with CSA (44.7 + 22.8 pg/mL) ( Figure 1) . ANCOVA showed that rIL-8 remained significantly higher (P , 0.001) in ACS after adjustment for all the variables that were significantly different between ACS and CSA patients (R 2 ¼ 0.314; for full model P , 0.001 P , 0.001).
As IL-8 load in erythrocyte membranes has not been extensively assessed in the general population, we assessed rIL-8 levels in an age and sex matched group of individuals with NCA as a mean of comparison. Student's t-test (P , 0.001) and ANCOVA (P , 0.001) accounting for differences between the two groups, showed that rIL-8 values were higher in ACS compared with patients without angiographic CAD (48.2 + 25.4 pg/mL). In contrast, rIL-8 was not significantly different between patients with NCA and those with CSA (t-test, P ¼ 0.796 and ANCOVA, P ¼ 0.940).
Likewise, CEM levels were significantly higher (t-test, P , 0.001 and ANCOVA, P , 0.001) in ACS compared with patients with NCA (80.2 + 12.1 mg/mg); no difference was observed between CSA and patients with NCA (t-test, P ¼ 0.197 and ANCOVA, P ¼ 0.491).
No differences were noted in plasma IL-8 levels among CSA (t-test, P ¼ 0.833 and ANCOVA, P ¼ 0.820), ACS (t-test, P ¼ 0.053 and ANCOVA, P ¼ 0.528), and patients with NCA (51.3 + 19.9 pg/mL). Likewise, plasma levels of IL-8 (pIL-8) were not different among CSA (56.5 + 36.6 pg/mL) and ACS (64.8 + 33.2 pg/mL) in both unadjusted (univariate Student's t-test, P ¼ 0.057) or adjusted (multivariable ANCOVA, P ¼ 0.280) comparisons. Table 2 summarizes values of rIL-8, pIL-8, and CEM in the three groups.
As it was expected, CRP levels were significantly higher (P , 0.001) in patients with ACS (31.3 + 28.2 mg/L) compared with those with CSA (4.7 + 3.5 mg/L). Patients with NCA had lower CRP levels (2.7 + 1.8 mg/L) compared with ACS (P , 0.001) and CSA (P , 0.001) patients. Table 3 summarizes results of simple logistic regression analysis for each of the three major biochemical indices (CEM, rIL-8, CRP) that could predict CAD instability. All the three parameters were predictive of ACS.
Prediction of coronary artery disease instability
After adjustment for all the variables that were different between the two groups (ACS, CSA) on univariate analysis (arterial hypertension, current smoking, therapy with nitrates, statins, b-blockers, calcium channel blockers, aspirin; and log triglyceride levels), multiple logistic regression analysis showed that rIL-8, CRP, and CEM levels continued to have an independent association with ACS ( Table 4) . When the three biochemical indices (rIL-8, CEM, and CRP) were included in the aforementioned covariate-adjusted logistic regression model in a stepwise fashion (covariates þ rIL-8 levels, covariates þ rIL-8 þ CRP levels, covariates þ rIL-8 þ CRP þ CEM levels), rIL-8 continued to be a significant and an independent predictor of ACS ( Table 4) . Finally, when the three under-investigation biochemical indices (rIL-8, CRP, and CEM) were included in the covariate-adjusted logistic regression model in an inverse stepwise fashion (covariates þ CRP levels, covariates þ CRP þ CEM levels, covariates þ CRP þ CEM þ rIL-8 levels) C-statistic and likelihood ratio test showed that rIL-8 levels added significantly to the predictive ability compared with CRP and CEM levels ( Table 5) .
Receiver-operating characteristics curve analysis
Consistent with the previous results, ROC analysis regarding predictive accuracy for CAD status showed that for rIL-8, the area under the curve was 0.826 (0.774-0.878); P , 0.001, for CEM 0.921 (0.886 -0.955); P , 0.001, and for CRP 0.831 (0.780 -0.882); P , 0.001. Albeit without controlling for possible cofounders, ROC analysis indicates that rIL-8 was a good marker of CAD instability, comparable with CRP levels (Figure 2) .
Correlation analysis
Correlation analysis in the entire patient population (n ¼ 238) showed a significant positive association between rIL-8 and CRP plasma levels (r ¼ 0.294, P , 0.001) while no correlation was found between plasma IL-8 and CRP levels (r ¼ 0.025, P ¼ 0.706). Of interest, plasma IL-8 and rIL-8 levels were positively correlated (r ¼ 0.283, P , 0.001). Furthermore, rIL-8 and CEM were also positively associated (r ¼ 0.409, P , 0.001).
As it was expected, 5 no association was found between CEM and: (i) serum total cholesterol concentration (r ¼ 0.047; P ¼ 0.472), LDL (r ¼ 0.011; P ¼ 0.865), (ii) HDL-cholesterol levels (r ¼ 20.043; P ¼ 0.512), and (iii) triglyceride levels (r ¼ 0.063; P ¼ 0.337) when patients with ACS and CSA were included. CEM levels were not correlated with number of diseased vessels (r ¼ 20.007, P ¼ 0.881) or with stenosis score (r ¼ 0.031, P ¼ 0.596). This was also the case for rIL-8 levels (for number of diseased vessels: r ¼ 20.028, P ¼ 0.579, and for stenosis score: r ¼ 0.017, P ¼ 0.746).
Subgroup analysis
The incidence of ACS in patients with CAD in relation to rIL-8 and CRP is shown in Figure 3 . It was observed that among CAD patients with low CRP levels (n ¼ 126, CRP ,5 mg/L), rIL-8 was significantly associated with the presence of ACS (OR log rIL-8/ SD 18.6 95% CI 5.2 -66.6, P , 0.001). Even among patients with CAD with high CRP levels (n ¼ 112, CRP !5 mg/L), rIL-8 was still predictive of ACS (OR log rIL-8/SD 4.7 95% CI 2.3 -9.6, P , 0.001). Furthermore, rIL-8 was a significant predictor of CAD instability across all quartiles of CRP, albeit stronger in the lower spectrum ( Figure 4) . observed between statin use and rIL-8 levels we compared the predictive ability for ACS of rIL-8 in both patients with and without statin treatment. In the subgroup of patients receiving statin treatment, rIL-8 levels were predictive of ACS (OR log rIL-8/SD 11.1 95% CI 3.6-34.2, P , 0.001). Furthermore, rIL-8 levels were also associated with ACS (OR log rIL-8/SD 3.9 95% CI 2.3 -6.5, P , 0.001) in the subgroup of patients not receiving statins.
The previous occurrence of an acute coronary event in some patients in the CSA group may obscure the designation of CAD clinical presentation as stable. We therefore, assessed the ability IL-8 content of erythrocyte membrane and ACS of rIL-8 to predict clinical instability in the subgroup of CSA patients without a history of ACS (n ¼ 166). We found that rIL-8 levels were associated with the occurrence of ACS (OR log rIL-8/SD 6.9 95% CI 3.6 -13.1, P , 0.001) in the subgroup of patients without a previous history of ACS.
Discussion
The present study is the first to report that IL-8 content in circulating erythrocyte membranes is higher in ACS compared with CSA patients. These results endorse and expand our previous findings 5 according to which high CEM levels were present in ACS patients. In the present study, rIL-8 was a marker of ACS independent of CRP and CEM concentrations. 27 Further, these findings were independent of leucocyte and lymphocyte count. 28 It was also found that rIL-8 content in the erythrocyte membranes was associated with circulating levels of CRP. That erythrocytes could play a role in plaque instability is biologically plausible. 1 Recent studies have shown that neovascularization is important in the development of atherosclerotic plaque and in its instability. 29 -31 The newly formed vessels may lead to the extravasation of erythrocytes within the atherosclerotic plaque. 7 Red cells rich in cholesterol may contribute to an abrupt volume expansion and to a change in the lipid composition of the plaque, thus the lipid core becomes rich in free cholesterol, 1,2,5 an important determinant of plaque vulnerability. 4, 6, 32, 33 Further, it is quite plausible that extravasated erythrocytes may initiate and propagate an inflammatory cascade 2, 4, 7, 8 within the atherosclerotic plaque, which may play a pathogenic role in CAD progression and plaque rupture. 9, 10, 34, 35 This inflammation cascade may be promoted by receptors present on erythrocyte membranes, which bind to a wide array of chemokines including IL-8 and monocyte chemotactic peptide-1. 4, 12, 36, 37 IL-8 is a C -X -C chemokine that has the potential of modulating atherosclerosis progression. 11 A number of studies have shown that IL-8 is present in human atherosclerotic plaques in patients with UA. 38 -44 IL-8 has been shown to be a potent chemotactic factor for T-lymphocytes 45 and monocytes. 46 In addition to its chemoattractant properties, it also possesses other plaque destabilizing effects. IL-8 contributes to smooth muscle cell migration and proliferation, 47 a possible source of matrix metalloproteinases, 48 and additionally down-regulates the action of inhibitors of metalloproteinases. 49 Further, IL-8 is a signal for angiogenesis, 43 an important mechanism of atherosclerotic plaque instability. 29 -31 Finally, it has been suggested that IL-8 is a key participant in the cross talk between coagulation activation and cytokine cascades.
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C-X-C chemokines may have also atheroprotective effects. Keratinocyte-derived chemokine (KC) the mouse ortholog of human growth-related oncogene (GRO-a)-a C -X -C chemokine-has been shown to exert a protective effect on plaque formation after endothelial denudation (endothelial wound injury) presumably by accelerated re-endothelialization. This implies that KC may exert a protective role in neointima formation especially in the setting of restenosis by accelerating endothelial recovery. 51 Our results are in agreement with that of de Winter et al. 24 who have shown that IL-8 is mainly bound to erythrocytes in patients suffering from an acute MI and their levels of rIL-8 were significantly higher compared with those in healthy controls. In contrast, other studies reported that plasma levels of IL-8 were significantly higher in ACS compared with CSA. 52, 53 An explanation for this disparity may be the timing of blood sampling in the ACS patient group. In the aforementioned studies 52, 53 blood samples were obtained during the acute phase of the event, whereas in our study blood was obtained 15 days after the acute event. It is known that circulating levels of IL-8 in ACS return to normal values within a few days from the onset of symptoms. 24 Thus, pIL-8 and rIL-8 levels are changing constantly for a few days after the acute event and steady-state condition is reached several days after the acute ischaemic syndrome. The present study was designed to assess the diagnostic ability of the aforementioned markers at steady-state condition. It should be emphasized that the present study demonstrated that erythrocyte membranes IL-8 level is increased in patients with ACS compared with CSA. At present, there is not sufficient information to suggest that rIL-8 is involved in the pathogenetic mechanisms related to unstable atherosclerotic plaque. Thus, the concept that erythrocytes-entrapped within the atherosclerotic plaque-propagating an inflammatory response and interfering with plaque instability at present is speculative. 54 This, however, does not detract from the fact that rIL-8 is at least a marker of CAD instability. In summary, this study showed that IL-8 contained in erythrocyte membranes is associated with the presence of ACS. It is quite plausible that intraplaque haemorrhage and consequently extravasated erythrocytes may contribute to plaque instability via inflammatory mechanisms, in addition to the enlargement of the necrotic lipid core. Thus-as suggested in previous studies from our group-erythrocytes may play an active role in the atherosclerotic plaque progression and in plaque instability.
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